MiNK Therapeutics (NASDAQ:INKT) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of MiNK Therapeutics (NASDAQ:INKT) from a hold rating to a sell rating in a research note published on Sunday morning.

A number of other brokerages also recently commented on INKT. Weiss Ratings reiterated a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Stock Performance

INKT stock opened at $12.40 on Friday. The company’s 50 day moving average price is $12.00 and its 200 day moving average price is $14.10. The firm has a market capitalization of $58.16 million, a price-to-earnings ratio of -4.09 and a beta of 0.34. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.21. Equities analysts forecast that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.